Lack of bromocriptine-induced reduction of predicted height in tall adolescents
Détails
ID Serval
serval:BIB_0182EFA3C26C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lack of bromocriptine-induced reduction of predicted height in tall adolescents
Périodique
Journal of Clinical Endocrinology and Metabolism
ISSN
0021-972X (Print)
Statut éditorial
Publié
Date de publication
08/1987
Volume
65
Numéro
2
Pages
355-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Aug
Research Support, Non-U.S. Gov't --- Old month value: Aug
Résumé
Fifteen girls and five boys with excessive predicted adult height (chronological age, 10.1-14.6 yr; bone age, 11.0-14.0 yr) were treated with bromocriptine (two doses; 2.5 mg/day) to reduce their final height. After a mean treatment period of 1.14 yr (range, 0.6-1.75 yr) we did not find a reduction of predicted adult height [difference, -0.5 +/- 3.5 (+/- SD) cm according to Bayley and Pinneau's tables (P = NS) and +0.2 +/- 2.5 (+/- SD) cm according to the method of Tanner (P = NS)]. Mean peak plasma GH concentrations after TRH administration before and during bromocriptine were 51.5 +/- 49.4 and 58.5 +/- 50.7 mU/L, respectively. The wide range of the GH values may be explained by physiological variation in this age group. After ingestion of 2.5 mg bromocriptine a significant increase in plasma GH occurred within 3 h in six adolescents tested. Our results do not support the concept that bromocriptine may reduce predicted adult height in tall adolescents by decreased GH secretion or acceleration of skeletal maturation.
Mots-clé
Adolescent
Age Determination by Skeleton
Body Height/*drug effects
Bromocriptine/*therapeutic use
Child
Female
Growth Hormone/blood
Humans
Male
Thyrotropin-Releasing Hormone/diagnostic use
Pubmed
Web of science
Création de la notice
25/01/2008 11:31
Dernière modification de la notice
20/08/2019 13:23